Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SCD | O00767 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24953812 | 1.00 | MAPT (0.53) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24952950 | 0.93 | MAPT (0.53) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24952945 | 0.90 | SCD (0.51) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24953830 | 0.90 | SCD (0.47) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24953932 | 0.90 | SCD (0.47) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24952949 | 0.89 | SCD (0.49) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24953492 | 0.89 | SCD (0.49) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24952891 | 0.89 | SCD (0.49) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24953674 | 0.88 | MAPT (0.51) | MAPTSCDLMNAKMT2AMEN1 | |
| SCHEMBL24953697 | 0.88 | MAPT (0.69) | MAPTSCDLMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | MAPT 3161/4885SCD 2396/4885LMNA 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.